{
  "document_info": {
    "title": "Pocket Guide for Asthma Management and Prevention",
    "publisher": "Global Initiative for Asthma (GINA)",
    "version": "Updated 2023",
    "target_audience": "Health Professionals",
    "scope": ["Adults", "Adolescents", "Children 6-11 years"]
  },
  "abbreviations_glossary": [
    {"term": "BDP", "definition": "Beclometasone dipropionate"},
    {"term": "COPD", "definition": "Chronic obstructive pulmonary disease"},
    {"term": "CYP450", "definition": "Cytochrome P450"},
    {"term": "DPI", "definition": "Dry powder inhaler"},
    {"term": "ED", "definition": "Emergency department"},
    {"term": "FeNO", "definition": "Fraction of exhaled nitric oxide"},
    {"term": "FEV1", "definition": "Forced expiratory volume in 1 second"},
    {"term": "FVC", "definition": "Forced vital capacity"},
    {"term": "GERD", "definition": "Gastroesophageal reflux disease"},
    {"term": "ICS", "definition": "Inhaled corticosteroids"},
    {"term": "ICS-LABA", "definition": "Combination ICS and LABA"},
    {"term": "LABA", "definition": "Long-acting beta2-agonist"},
    {"term": "LAMA", "definition": "Long-acting muscarinic antagonist"},
    {"term": "LTRA", "definition": "Leukotriene receptor antagonist"},
    {"term": "MART", "definition": "Maintenance and Reliever Therapy"},
    {"term": "NSAID", "definition": "Nonsteroidal anti-inflammatory drug"},
    {"term": "OCS", "definition": "Oral corticosteroids"},
    {"term": "PEF", "definition": "Peak expiratory flow"},
    {"term": "pMDI", "definition": "Pressurized metered dose inhaler"},
    {"term": "SABA", "definition": "Short-acting beta2-agonist"},
    {"term": "SLIT", "definition": "Sublingual immunotherapy"},
    {"term": "TSLP", "definition": "Thymic stromal lymphopoietin"}
  ],
  "disease_definition": {
    "primary_definition": "A chronic disease usually characterized by airway inflammation.",
    "defining_features": {
      "symptoms": ["Wheeze", "Shortness of breath", "Chest tightness", "Cough"],
      "symptom_characteristics": ["Vary over time", "Vary in intensity"],
      "physiologic_feature": "Variable expiratory airflow limitation"
    },
    "pathophysiology_mechanisms": [
      "Bronchoconstriction (airway narrowing)",
      "Airway wall thickening",
      "Increased mucus"
    ]
  },
  "diagnosis_logic": {
    "symptom_patterns": {
      "typical_characteristics": [
        "More than one symptom (wheeze, shortness of breath, cough, chest tightness)",
        "Symptoms occur variably over time and intensity",
        "Symptoms often worse at night or on waking",
        "Triggered by exercise, laughter, allergens, cold air",
        "Worsen with viral infections"
      ]
    },
    "diagnostic_evidence_criteria": {
      "bronchodilator_reversibility": {
        "adults_adolescents": {
          "condition": "Post-bronchodilator FEV1 increase",
          "threshold_volume": ">200 mL",
          "threshold_percentage": ">12% from baseline"
        },
        "children": {
          "condition": "Post-bronchodilator FEV1 increase",
          "threshold_percentage": ">12% of predicted value"
        }
      },
      "pef_variability": {
        "calculation": "(Highest - Lowest) / Mean of Highest and Lowest",
        "frequency": "Twice daily readings over 1-2 weeks",
        "adult_threshold": ">10%",
        "child_threshold": ">13%"
      },
      "anti_inflammatory_trial": {
        "duration": "4 weeks",
        "criteria_adults": "FEV1 increase >12% and >200 mL from baseline",
        "criteria_children": "FEV1 increase >12% of predicted"
      }
    },
    "diagnostic_flowchart_steps": [
      {
        "step_id": 1,
        "query": "Does patient have respiratory symptoms typical of asthma?",
        "if_no": "Further history and tests for alternative diagnoses."
      },
      {
        "step_id": 2,
        "query": "Does detailed history/examination support asthma diagnosis?",
        "if_no": "Further history and tests for alternative diagnoses."
      },
      {
        "step_id": 3,
        "query": "Is patient already taking ICS-containing treatment?",
        "if_yes": "See GINA 2023 report for diagnostic steps in treated patients.",
        "if_no": "Perform spirometry/PEF with reversibility test."
      },
      {
        "step_id": 4,
        "query": "Do results support asthma diagnosis?",
        "if_yes": "Treat for ASTHMA.",
        "if_no": "Repeat testing (symptomatic/early morning/withholding meds) or Arrange other tests (bronchial challenge)."
      },
      {
        "step_id": "Empiric Treatment Path",
        "condition": "Clinical urgency and other diagnoses unlikely",
        "action": "Start empiric initial treatment -> Review response in 1-3 months."
      }
    ]
  },
  "assessment_protocols": {
    "symptom_control_assessment": {
      "time_window": "Past 4 weeks",
      "questions": [
        "Daytime symptoms >2/week?",
        "Any night waking due to asthma?",
        "SABA reliever needed >2/week?",
        "Any activity limitation due to asthma?"
      ],
      "scoring_levels": {
        "well_controlled": "0 questions answered Yes",
        "partly_controlled": "1-2 questions answered Yes",
        "uncontrolled": "3-4 questions answered Yes"
      }
    },
    "risk_factors": {
      "exacerbation_risk_independent_of_symptoms": [
        "Uncontrolled asthma symptoms",
        "SABA overuse (>=3 canisters/year)",
        "Inadequate ICS (not prescribed, poor adherence, incorrect technique)",
        "Low FEV1 (<60% predicted)",
        "High bronchodilator responsiveness",
        "Major psychological problems (anxiety, depression)",
        "Exposures (smoking, allergens, pollution)",
        "Comorbidities (obesity, rhinosinusitis, GERD, food allergy, pregnancy)",
        "Type 2 inflammatory markers (high eosinophils, high FeNO)",
        "History of intubation/ICU for asthma",
        "One or more severe exacerbations in last 12 months"
      ],
      "persistent_airflow_limitation_risks": [
        "Preterm birth / low birth weight",
        "Chronic mucus hypersecretion",
        "Lack of ICS treatment with history of severe exacerbation",
        "Tobacco smoke/chemical exposure",
        "Low FEV1",
        "Sputum or blood eosinophilia"
      ],
      "medication_side_effect_risks": [
        "Frequent OCS",
        "Long-term high-dose/potent ICS",
        "Taking P450 inhibitors (ritonavir, ketoconazole, itraconazole)"
      ]
    }
  },
  "treatment_tracks_adults_adolescents": {
    "track_1": {
      "status": "Preferred",
      "controller": "ICS-formoterol",
      "reliever": "As-needed low-dose ICS-formoterol",
      "mechanism_benefit": "Reduces risk of severe exacerbations compared to SABA reliever regimens; simpler regimen.",
      "usage_steps": {
        "step_1": "As-needed only low dose ICS-formoterol.",
        "step_2": "As-needed only low dose ICS-formoterol.",
        "step_3": "Low dose maintenance ICS-formoterol + As-needed reliever.",
        "step_4": "Medium dose maintenance ICS-formoterol + As-needed reliever.",
        "step_5": "Add-on LAMA; Refer for assessment; Consider high dose maintenance ICS-formoterol."
      }
    },
    "track_2": {
      "status": "Alternative",
      "controller": "ICS-containing maintenance",
      "reliever": "As-needed SABA or As-needed ICS-SABA",
      "safety_prerequisite": "Check if patient is likely to adhere to daily controller. Otherwise, risk of SABA-only outcomes.",
      "usage_steps": {
        "step_1": "Take low dose ICS whenever SABA taken.",
        "step_2": "Low dose maintenance ICS daily.",
        "step_3": "Low dose maintenance ICS-LABA daily.",
        "step_4": "Medium/High dose maintenance ICS-LABA daily.",
        "step_5": "Add-on LAMA; Refer for assessment; Consider high dose ICS-LABA."
      }
    }
  },
  "initial_treatment_selection_logic": {
    "adults_adolescents": [
      {
        "symptoms": "Less than 4-5 days a week",
        "track_1_recommendation": "Steps 1-2: As-needed low dose ICS-formoterol",
        "track_2_recommendation": "Step 1: Take ICS whenever SABA taken"
      },
      {
        "symptoms": "Most days OR waking with asthma once a week or more",
        "track_1_recommendation": "Step 3: Low dose maintenance ICS-formoterol",
        "track_2_recommendation": "Step 3: Low dose maintenance ICS-LABA"
      },
      {
        "symptoms": "Daily symptoms OR waking with asthma once a week or more AND Low lung function",
        "track_1_recommendation": "Step 4: Medium dose maintenance ICS-formoterol",
        "track_2_recommendation": "Step 4: Medium/High dose maintenance ICS-LABA"
      },
      {
        "presentation": "Severely uncontrolled asthma or acute exacerbation",
        "action": "Short course OCS; Start High Dose ICS or Medium Dose ICS-formoterol (Step 4)"
      }
    ],
    "children_6_11_years": [
      {
        "symptoms": "Less than twice a month",
        "recommendation": "Step 1: Low dose ICS whenever SABA taken"
      },
      {
        "symptoms": "Twice a month or more, but less than daily",
        "recommendation": "Step 2: Daily low dose ICS"
      },
      {
        "symptoms": "Most days OR waking with asthma once a week or more",
        "recommendation": "Step 3: Low dose ICS-LABA OR Medium dose ICS OR Very low dose ICS-formoterol MART"
      },
      {
        "symptoms": "Most days OR waking with asthma once a week or more AND Low lung function",
        "recommendation": "Step 4: Medium dose ICS-LABA OR Low dose ICS-formoterol MART; Refer for expert advice"
      }
    ]
  },
  "medication_dosage_tables": {
    "adults_adolescents_ics_daily_mcg": [
      {"drug": "Beclometasone dipropionate (pMDI, HFA)", "low_dose": "200-500", "medium_dose": ">500-1000", "high_dose": ">1000"},
      {"drug": "Beclometasone dipropionate (DPI or pMDI extrafine)", "low_dose": "100-200", "medium_dose": ">200-400", "high_dose": ">400"},
      {"drug": "Budesonide (DPI or pMDI)", "low_dose": "200-400", "medium_dose": ">400-800", "high_dose": ">800"},
      {"drug": "Ciclesonide (extrafine)", "low_dose": "80-160", "medium_dose": ">160-320", "high_dose": ">320"},
      {"drug": "Fluticasone furoate (DPI)", "low_dose": "100", "medium_dose": "100", "high_dose": "200"},
      {"drug": "Fluticasone propionate (DPI)", "low_dose": "100-250", "medium_dose": ">250-500", "high_dose": ">500"},
      {"drug": "Fluticasone propionate (pMDI)", "low_dose": "100-250", "medium_dose": ">250-500", "high_dose": ">500"},
      {"drug": "Mometasone furoate (DPI)", "low_dose": "200", "medium_dose": "200", "high_dose": "400"},
      {"drug": "Mometasone furoate (pMDI)", "low_dose": "200-400", "medium_dose": "400", "high_dose": ">400"}
    ],
    "children_6_11_ics_daily_mcg": [
      {"drug": "Beclometasone dipropionate (pMDI, HFA)", "low_dose": "100-200", "medium_dose": ">200-400", "high_dose": ">400"},
      {"drug": "Beclometasone dipropionate (extrafine)", "low_dose": "50-100", "medium_dose": ">100-200", "high_dose": ">200"},
      {"drug": "Budesonide (DPI)", "low_dose": "100-200", "medium_dose": ">200-400", "high_dose": ">400"},
      {"drug": "Budesonide (nebules)", "low_dose": "250-500", "medium_dose": ">500-1000", "high_dose": ">1000"},
      {"drug": "Ciclesonide (extrafine)", "low_dose": "80", "medium_dose": ">80-160", "high_dose": ">160"},
      {"drug": "Fluticasone furoate (DPI)", "low_dose": "50", "medium_dose": "N/A", "high_dose": "N/A"},
      {"drug": "Fluticasone propionate (DPI)", "low_dose": "50-100", "medium_dose": ">100-200", "high_dose": ">200"},
      {"drug": "Fluticasone propionate (pMDI)", "low_dose": "50-100", "medium_dose": ">100-200", "high_dose": ">200"},
      {"drug": "Mometasone furoate (pMDI)", "low_dose": "100", "medium_dose": "200", "high_dose": ">200"}
    ],
    "track_1_mart_regimens": {
      "budesonide_formoterol_dpi_200_6": {
        "step_1_2": "1 inhalation whenever needed",
        "step_3": "1 inhalation once daily PLUS 1 inhalation whenever needed",
        "step_4": "1 inhalation twice daily PLUS 1 inhalation whenever needed",
        "step_5": "2 inhalations twice daily PLUS 1 inhalation whenever needed",
        "max_daily_limit": "12 inhalations total (72 mcg formoterol)"
      },
      "beclometasone_formoterol_pmdi_100_6": {
        "step_3": "1 inhalation twice daily PLUS 1 inhalation whenever needed",
        "step_4": "2 inhalations twice daily PLUS 1 inhalation whenever needed",
        "step_5": "2 inhalations twice daily PLUS 1 inhalation whenever needed",
        "max_daily_limit": "8 inhalations total (48 mcg formoterol)"
      }
    }
  },
  "exacerbation_management_protocols": {
    "primary_care_assessment_adults": {
      "mild_moderate": {
        "clinical_signs": ["Talks in phrases", "Prefers sitting to lying", "Not agitated", "Respiratory rate increased", "Accessory muscles not used"],
        "vitals": {"pulse": "100-120 bpm", "o2_sat": "90-95%"},
        "lung_function": "PEF >50% predicted or best",
        "treatment": {
          "saba": "4-10 puffs by pMDI + spacer, repeat every 20 mins for 1 hour",
          "prednisolone": "40-50 mg (Adults), 1-2 mg/kg max 40 mg (Children)",
          "oxygen": "Target saturation 93-95% (Adults), 94-98% (Children)"
        }
      },
      "severe": {
        "clinical_signs": ["Talks in words", "Sits hunched forwards", "Agitated", "Respiratory rate >30/min", "Accessory muscles in use"],
        "vitals": {"pulse": ">120 bpm", "o2_sat": "<90%"},
        "lung_function": "PEF <=50% predicted or best",
        "treatment": "Transfer to acute care facility. While waiting: Give SABA, Ipratropium bromide, Oxygen, Systemic corticosteroid"
      },
      "life_threatening": {
        "clinical_signs": ["Drowsy", "Confused", "Silent chest"],
        "treatment": "URGENT transfer to acute care facility"
      }
    },
    "written_action_plan_instructions": {
      "for_track_1_patients": {
        "reliever_instruction": "Take extra doses of low-dose ICS-formoterol whenever needed.",
        "maintenance_instruction": "Continue usual maintenance doses.",
        "medical_attention_threshold": "Rapidly deteriorating OR needing >12 inhalations/day (Budesonide-Formoterol) or >8 inhalations/day (Beclometasone-Formoterol)."
      },
      "for_track_2_patients_saba_reliever": {
        "reliever_instruction": "Take SABA when needed.",
        "maintenance_instruction_ics_only": "Increase maintenance ICS dose by 4x (Adults). Note: 5x increase in children not likely effective.",
        "maintenance_instruction_ics_formoterol": "Increase maintenance dose to 4x usual dose (observe daily max).",
        "maintenance_instruction_ics_other_laba": "Step up to higher dose formulation or add separate ICS inhaler.",
        "medical_attention_threshold": "Rapidly deteriorating OR need SABA again within 3 hours."
      }
    }
  },
  "special_populations_guidance": {
    "covid_19": {
      "medication_advice": "Continue ICS and biologics. Stopping ICS increases risk of dangerous worsening. Avoid nebulizers to prevent viral transmission.",
      "risk_clarification": "People with well-controlled asthma NOT at increased risk of severe COVID-19. Risk increases if recent OCS use or hospitalization.",
      "vaccination": "Recommended. Do not administer biologic and vaccine on same day.",
      "drug_interaction_warning": "Ritonavir-boosted nirmatrelvir (Paxlovid) interaction with Salmeterol or Vilanterol may cause cardiac toxicity."
    },
    "pregnancy": {
      "monitoring_frequency": "Every 4-6 weeks.",
      "medication_safety": "Benefits of active treatment outweigh potential risks. Do NOT step down treatment. Treat exacerbations aggressively.",
      "labor_delivery": "Stress-dose hydrocortisone if on high-dose ICS or OCS >2 weeks in last 6 months."
    },
    "surgery": {
      "protocol": "Achieve good control pre-op. Maintain ICS. Give stress-dose hydrocortisone if on long-term high-dose ICS or recent OCS."
    },
    "obesity": {
      "impact": "Weight loss of 5-10% can improve asthma control."
    },
    "aspirin_exacerbated_respiratory_disease_aerd": {
      "clinical_triad": "Severe asthma + Nasal polyposis + Reaction to NSAIDs.",
      "management": "Avoid NSAIDs. ICS is mainstay. LTRA may be useful. Desensitization possible in specialist centers."
    }
  },
  "inhaler_technique_adherence": {
    "technique_failure_rate": "Up to 80% of patients cannot use inhaler correctly.",
    "intervention_steps": [
      "Choose appropriate device for patient skills/cost",
      "Check technique against checklist",
      "Correct with physical demonstration",
      "Re-check 2-3 times"
    ],
    "adherence_failure_rate": "At least 50% of adults/children do not take medications as prescribed.",
    "proven_interventions": [
      "Shared decision-making",
      "Electronic inhaler reminders",
      "Home visits",
      "Reviewing dispensing records"
    ]
  },
  "glossary_medication_mechanisms": {
    "ics": {
      "role": "Most effective anti-inflammatory. Reduces symptoms/exacerbations.",
      "side_effects_local": "Oropharyngeal candidiasis, dysphonia.",
      "side_effects_systemic": "Osteoporosis, cataract, glaucoma (long-term high dose)."
    },
    "laba": {
      "safety_warning": "Should NOT be used without ICS in asthma.",
      "side_effects": "Tachycardia, headache, cramps."
    },
    "ltra": {
      "efficacy": "Less effective than ICS.",
      "safety_warning": "FDA boxed warning for Montelukast (serious mental health effects)."
    },
    "lama": {
      "role": "Add-on at Step 5. Modest lung function improvement. No symptom benefit."
    },
    "biologics": {
      "anti_ige": "Omalizumab (Severe allergic)",
      "anti_il5": "Mepolizumab, Reslizumab (Severe eosinophilic)",
      "anti_il5r": "Benralizumab (Severe eosinophilic)",
      "anti_il4r": "Dupilumab (Severe Type 2)",
      "anti_tslp": "Tezepelumab (Severe asthma)"
    }
  }
}